Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology

Cesare Gridelli, Paolo Antonio Ascierto, Massimo Barberis, Enriqueta Felip, Edward B. Garon, Mary O’brien, Suresh Senan, Francesca Casaluce, Assunta Sgambato, Vali Papadimitrakopoulou, Filippo De Marinis

Research output: Contribution to journalReview article

Abstract

Introduction: The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions and safety profile of these new agents, all support the role of immunotherapy in the cancer treatment pathway or paradigm. Areas covered: The authors discuss the recent advances in the understanding of immunology and antitumor immune responses that have led to the development of new immunotherapies, including monoclonal antibodies that inhibit immune checkpoint pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab. Expert opinion: Ongoing research will dictate future strategies, including the potential incorporation of immunotherapy in stage dependent treatment settings (early stage locally advanced disease and first line therapy for metastatic disease). Immunotherapy combinations are promising avenues, and careful selection of patients, doses of each agent and information supporting strategies (i.e. concomitant or sequential) is still needed.

Original languageEnglish
Pages (from-to)1479-1489
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Oncology
Non-Small Cell Lung Carcinoma
Immunotherapy
Thorax
Cells
CTLA-4 Antigen
Immunology
Immune system
Tumors
Monoclonal Antibodies
Data storage equipment
Expert Testimony
Therapeutics
Allergy and Immunology
Patient Selection
Immune System
Neoplasms
Safety
Research
pembrolizumab

Keywords

  • Combination therapies
  • immune checkpoint inhibitors
  • immune-related toxicity
  • nivolumab
  • pembrolizumab
  • programmed death-1 (PD-1)

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Immunotherapy of non-small cell lung cancer : report from an international experts panel meeting of the Italian association of thoracic oncology. / Gridelli, Cesare; Ascierto, Paolo Antonio; Barberis, Massimo; Felip, Enriqueta; Garon, Edward B.; O’brien, Mary; Senan, Suresh; Casaluce, Francesca; Sgambato, Assunta; Papadimitrakopoulou, Vali; De Marinis, Filippo.

In: Expert Opinion on Biological Therapy, Vol. 16, No. 12, 01.12.2016, p. 1479-1489.

Research output: Contribution to journalReview article

Gridelli, Cesare ; Ascierto, Paolo Antonio ; Barberis, Massimo ; Felip, Enriqueta ; Garon, Edward B. ; O’brien, Mary ; Senan, Suresh ; Casaluce, Francesca ; Sgambato, Assunta ; Papadimitrakopoulou, Vali ; De Marinis, Filippo. / Immunotherapy of non-small cell lung cancer : report from an international experts panel meeting of the Italian association of thoracic oncology. In: Expert Opinion on Biological Therapy. 2016 ; Vol. 16, No. 12. pp. 1479-1489.
@article{46a94a66fcd740fc9b7bf5f5a605daef,
title = "Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology",
abstract = "Introduction: The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions and safety profile of these new agents, all support the role of immunotherapy in the cancer treatment pathway or paradigm. Areas covered: The authors discuss the recent advances in the understanding of immunology and antitumor immune responses that have led to the development of new immunotherapies, including monoclonal antibodies that inhibit immune checkpoint pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab. Expert opinion: Ongoing research will dictate future strategies, including the potential incorporation of immunotherapy in stage dependent treatment settings (early stage locally advanced disease and first line therapy for metastatic disease). Immunotherapy combinations are promising avenues, and careful selection of patients, doses of each agent and information supporting strategies (i.e. concomitant or sequential) is still needed.",
keywords = "Combination therapies, immune checkpoint inhibitors, immune-related toxicity, nivolumab, pembrolizumab, programmed death-1 (PD-1)",
author = "Cesare Gridelli and Ascierto, {Paolo Antonio} and Massimo Barberis and Enriqueta Felip and Garon, {Edward B.} and Mary O’brien and Suresh Senan and Francesca Casaluce and Assunta Sgambato and Vali Papadimitrakopoulou and {De Marinis}, Filippo",
year = "2016",
month = "12",
day = "1",
doi = "10.1080/14712598.2016.1234602",
language = "English",
volume = "16",
pages = "1479--1489",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Immunotherapy of non-small cell lung cancer

T2 - report from an international experts panel meeting of the Italian association of thoracic oncology

AU - Gridelli, Cesare

AU - Ascierto, Paolo Antonio

AU - Barberis, Massimo

AU - Felip, Enriqueta

AU - Garon, Edward B.

AU - O’brien, Mary

AU - Senan, Suresh

AU - Casaluce, Francesca

AU - Sgambato, Assunta

AU - Papadimitrakopoulou, Vali

AU - De Marinis, Filippo

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Introduction: The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions and safety profile of these new agents, all support the role of immunotherapy in the cancer treatment pathway or paradigm. Areas covered: The authors discuss the recent advances in the understanding of immunology and antitumor immune responses that have led to the development of new immunotherapies, including monoclonal antibodies that inhibit immune checkpoint pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab. Expert opinion: Ongoing research will dictate future strategies, including the potential incorporation of immunotherapy in stage dependent treatment settings (early stage locally advanced disease and first line therapy for metastatic disease). Immunotherapy combinations are promising avenues, and careful selection of patients, doses of each agent and information supporting strategies (i.e. concomitant or sequential) is still needed.

AB - Introduction: The potential long term survival gain, related to immune adaptability and memory, the potential activity across multiple tumour types through targeting the immune system, and the opportunity for combinations offered by the unique mechanism of actions and safety profile of these new agents, all support the role of immunotherapy in the cancer treatment pathway or paradigm. Areas covered: The authors discuss the recent advances in the understanding of immunology and antitumor immune responses that have led to the development of new immunotherapies, including monoclonal antibodies that inhibit immune checkpoint pathways, such as Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4). Currently, two PD-1 inhibitors are available in clinical practice for treatment of advanced non-small cell lung cancer (NSCLC): nivolumab and pembrolizumab. Expert opinion: Ongoing research will dictate future strategies, including the potential incorporation of immunotherapy in stage dependent treatment settings (early stage locally advanced disease and first line therapy for metastatic disease). Immunotherapy combinations are promising avenues, and careful selection of patients, doses of each agent and information supporting strategies (i.e. concomitant or sequential) is still needed.

KW - Combination therapies

KW - immune checkpoint inhibitors

KW - immune-related toxicity

KW - nivolumab

KW - pembrolizumab

KW - programmed death-1 (PD-1)

UR - http://www.scopus.com/inward/record.url?scp=84994388924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994388924&partnerID=8YFLogxK

U2 - 10.1080/14712598.2016.1234602

DO - 10.1080/14712598.2016.1234602

M3 - Review article

VL - 16

SP - 1479

EP - 1489

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -